Cargando…
The correlation of serum sPD-1 and sPD-L1 levels with clinical, pathological characteristics and lymph node metastasis in nonsmall cell lung cancer patients
BACKGROUND/AIM: Significant advances have been achieved in immunotherapy for the treatment of lung cancer. It is known that tumor cells and cells in the tumor microenvironment express high amounts of programmed cell death ligand 1 (PD-L1). These PD-L1s interact with programmed cell death protein 1 (...
Autores principales: | ANCIN, Burcu, ÖZERCAN, Mesut Melih, YILMAZ, Yiğit, UYSAL, Serkan, KUMBASAR, Ulaş, SARIBAŞ, Zeynep, DİKMEN, Erkan, DOĞAN, Rıza, DEMİRCİN, Metin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Scientific and Technological Research Council of Turkey (TUBITAK)
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10387869/ https://www.ncbi.nlm.nih.gov/pubmed/36326416 http://dx.doi.org/10.55730/1300-0144.5407 |
Ejemplares similares
-
Can sPD-1 and sPD-L1 Plasma Concentrations Predict Treatment Response among Patients with Extraparenchymal Neurocysticercosis?
por: Toledo, Andrea, et al.
Publicado: (2023) -
Molecular Mechanism of Expression Changes of Immunological Indexes of PD-1/sPD-L1 after Radiotherapy in Nonsmall Cell Lung Cancer
por: Qu, Yanli, et al.
Publicado: (2021) -
An unexpected complication of videothoracoscopic lobectomy: late RIMA bleeding
por: Ancın, Burcu, et al.
Publicado: (2022) -
Incidental pulmonary arteriovenous malformation
por: Ancın, Burcu, et al.
Publicado: (2023) -
Soluble programmed death-1 (sPD-1) and programmed death ligand 1 (sPD-L1) as potential biomarkers for the diagnosis and prognosis of glioma patients
por: Liu, Shujun, et al.
Publicado: (2020)